video
Webinar: Plasmid platform facilitates transition to clinic
Discover how a plasmid DNA manufacturing platform process is helpful from preclinical studies to scaling production for late-stage and commercial needs.
List view / Grid view
Biopharmaceuticals
whitepaper
Whitepaper: Cancer biomarkers for immunohistochemistry
Streamline your cancer research using this guide that groups antibodies against critical cancer biomarkers according to biomarker type or tissue type.
news
Simcere receives clearance to investigate a bi-functional fusion protein drug
The FDA has cleared the Simcere's investigational new drug application for SIM0237, an anti-PD-L1/IL-15 bi-functional fusion protein, for the treatment of adult patients with advanced solid tumours.
news
FDA clears Cellenkos IND application for potential ALS treatment
Following FDA clearance, Cellenkos will initiate Phase I and Phase Ib trials of CK0803, allogeneic regulatory T cells, in patients with ALS.
whitepaper
ebook: Current and emerging strategies for engineered cell therapies: cancer immunotherapy
This exclusive ebook takes an in-depth look at recent developments in the field of cancer immunotherapy, with expert interviews exploring how researchers are advancing next-generation cell therapies into the clinic.
whitepaper
Application note: Afucosylated mAb expression & antibody efficacy
Sino Biological’s “FucoFree” eukaryotic expression system provides high-yield and high-throughput afucosylated monoclonal antibody (mAb) production.
news
Decibel Therapeutics submits IND application for hearing loss gene therapy candidate
Decibel Therapeutics has submitted an IND application for a Phase I/II trial of DB-OTO, a gene therapy candidate to restore hearing.
webinar
Power up your LNP and AAV sample prep with Unagi
12 October 2022 | By Unchained Labs
Watch this on-demand webinar to see first-hand data results demonstrating the power and flexibility of Unagi for nucleic acids, LNPs and AAVs.
article
Advancing vaccines with extracellular vesicles
Dr Christopher Locher, Versatope Therapeutics, explains why bacterial extracellular vesicles are ideally suited for recombinant vaccines because target antigens can be expressed as fusion proteins and targeted to the lumen, membrane or surface of the vesicles. These nano-size vesicles represent a potentially safe and simple subunit vaccine delivery platform that…
whitepaper
Application note: Flow cytometry platform
Compendium of iQue® advanced flow cytometry platform application posters: Antibody discovery and immuno-oncology.
whitepaper
Whitepaper: Disease state primary cells bring verification and validation studies closer to real-world results
Discover how BioIVT’s portfolio of disease state LEUKOMAX® leukopaks and PBMCs can serve as representative starting materials for autologous cell therapy research.
whitepaper
Application note: Studying Avi-tag protein interactions by SPR
Learn how R&D Systems™ Avi-tag biotinylated proteins can be used as an alternative to amine biotin coupling in surface plasmon resonance experiments.
whitepaper
Whitepaper: Isolation of tumour infiltrating lymphocytes from dissociated tumour cells
Discover how BioIVT’s dissociated tumour cells (DTCs) can be used for tumour-infiltrating lymphocyte (TIL) cell therapy research.
article
Drug Target Review Synthetic Biology ebook 2022
Within this ebook are features on synthetic biology, covering synthetic biotics and their potential to treat a wide range of diseases and conditions, while another piece examines the therapeutic directions the synthetic biology field will likely take in the future.
article
Monoclonal antibodies as a strategy to fight cancer
In this exclusive Q&A, Dr Veysel Kayser, Associate Professor at the University of Sydney, Australia, outlines why monoclonal antibodies (mAbs) are such an important tool to combat cancer. He also relates his recent research, as well as the latest trends in the industry.